We examined whether serum B cell activating factor (BAFF) is useful for predicting the remission of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following rituximab treatment. We used the Birmingham Vasculitis Activity Score (BVAS) 2008 version 3 for the evaluation of 27 patients with AAV 6 months after rituximab treatment. Those with BVAS = 0 achieved remission, whereas those with BVAS score > 0 did not achieve remission. We considered changes in serum BAFF before rituximab treatment, 1 month after treatment, and 6 months after treatment. In the remission group, the serum BAFF increased consistently. In the non-achieved group, serum BAFF was within the normal range. In addition, there was no statistically significant difference between the two groups in terms of serum BAFF before and 1 month after rituximab treatment. However, the serum BAFF level at 6 months after rituximab treatment was significantly higher in the remission group than in the non-achieved group. If serum BAFF does not increase after 6 months of rituximab in AAV, it may be assumed that there are residual B cells and plasma cells in the tissues. Enhanced treatment targeting B cells, including re-administration of rituximab or the addition of other immunosuppressive drugs, should be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/25785826.2022.2094592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
T cell immuno-phenotyping : a source of predictive biomarkers for autoimmune hepatitis relapse.
Sci Rep
October 2024
Nantes Université, CHU Nantes, INSERM, Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, F-44000, Nantes, France.
Article Synopsis
- Relapse after stopping immunosuppression treatment is common in Autoimmune Hepatitis (AIH) patients, and there's a need for better non-invasive biomarkers to predict this risk.
- The study analyzed blood samples from 58 active AIH patients, 56 in remission, and 31 with NASH, focusing on the levels of activated T cell subsets and the cytokine BAFF.
- Results showed that increased frequencies of certain activated T cells and high BAFF levels in remission patients were strongly linked to a higher chance of relapse after treatment withdrawal, suggesting these could serve as useful biomarkers for monitoring AIH.
B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
Int J Mol Sci
October 2024
Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Article Synopsis
- The BAFF-APRIL system is important in systemic lupus erythematosus (SLE) as it helps B cells survive and contribute to autoimmunity; this study examined BCMA expression in B cell subsets in SLE patients and healthy controls.
- SLE patients showed higher BCMA expression on B cells compared to healthy controls, with notable increases in memory B cells and a correlation between BCMA levels and disease markers like anti-dsDNA antibodies.
- Belimumab treatment reduced BCMA expression and other components of the BAFF-APRIL system, indicating its potential as both a treatment strategy and a biomarker for monitoring disease activity in SLE.
State-of-Art Therapeutics in IgA Nephropathy.
Indian J Nephrol
June 2024
Department of Medicine, Division of Nephrology, University of Alabama, Birmingham, USA.
Article Synopsis
- - Immunoglobulin-A nephropathy (IgAN) is the leading form of primary glomerulonephritis globally, with about 40% of patients eventually facing end-stage kidney disease (ESKD) within 30 years post-diagnosis due to immune complex formation caused by elevated Gd-IgA1 levels.
- - Current management focuses on supportive care using medications like renin-angiotensin system inhibitors and sodium-glucose transporter inhibitors to help control proteinuria, with recent advances leading to approvals for new treatments like budesonide and sparsentan.
- - Ongoing research is exploring novel therapies targeting different pathways involved in IgAN, including those affecting Gd-IgA1 production and the complement system,
Changes in the immune microenvironment during plasma cell tumor development in the IL6Myc mouse model of human multiple myeloma.
Exp Cell Res
October 2024
Department of Oncology and Hematology, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250001, China. Electronic address:
Immune reconstitution and evolution of B-cell-stimulating cytokines after R-CHOP therapy for HIV-associated DLBCL.
Blood Adv
December 2024
Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France.
HIV infection is associated with an increased risk of diffuse large B-cell lymphoma (DLBCL). In this prospective study, we analyzed the evolution of B-cell activating cytokines (interleukin-6 [IL-6], IL-10, and B-cell activating factor [BAFF]) and main functional subsets of circulating B and T cells in 51 patients with HIV-associated DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone). R-CHOP therapy was associated with a decrease of IL-10, whereas IL-6 levels fluctuated, and BAFF levels increased during the first 3 months and decreased thereafter.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!